

Scientific Program

Thursday, October 13, 2022

- 08:30-11:30** **Pre-Congress Workshop 1:
Breast cancer in young women: Understanding differences
to optimise outcomes** **Hall A (Great Hall 1)**
- Chairpersons:** **Sanjeev Kumar, Sydney, Australia**
 Jenny Gilchrist, Sydney, Australia
- 08:30-09:00** Fertility and breast cancer
 Ying Li, Sydney, Australia
- 09:00-09:30** Management of menopausal side effects
 Martha Hickey, Melbourne, Australia
- 09:30-10:00** Goserelin (Zoladex) in young women
 Prudence Francis, Melbourne, Australia
- 10:00-10:20* *Coffee break*
- 10:20-11:10** The art of oncology: Treating young women with a focus on pregnancy after breast cancer
 Ann Partridge, Boston, MA, USA
- 11:10-11:30** Q&A
-
- 08:30-11:30** **Pre-Congress Workshop 2:
Contrast based breast imaging** **Hall C (Room M1)**
- Chairperson:** **Nick Repin, Lismore, Australia**
- 08:30-08:35** Welcome
 Nick Repin, Lismore, Australia
- 08:35-08:55** Implementation of Contrast Imaging: Challenges and opportunities
 Allison Rose, Melbourne, Australia
- 08:55-09:40** Indications for Contrast Imaging
 Julia Camps Herrero, Valencia, Spain
- 09:40-10:00** Contrast Enhanced Mammography (CEM) in surveillance 15/5 Q&A
 Allison Rose, Melbourne, Australia
- 10:00-10:30* *Coffee break*
- 10:30-11:30** MDM hypothetical-case presentations and discussion
 Julia Camps Herrero, Valencia, Spain
 Allison Rose, Melbourne, Australia
 Bruce Mann, Melbourne, Australia
 Michael Christie, Melbourne, Australia

- 08:30-11:30** **Pre-Congress Workshop 3:**
Bioethical dilemmas: Q&A, cases and discussion **Hall D (Room M2)**
- Chairperson:** **Jennifer O’Sullivan, Sydney, Australia**
- 08:30-10:00** Cases and discussion
David Kirchhoffer, Brisbane, Australia
Bridget Pratt, Brisbane, Australia
- 10:00-10:20* *Coffee break*
- 10:20-11:30** Cases and discussion contd.
- 11:30-12:30* *Lunch break*
- 12:30-15:30** **Pre-Congress Workshop 4:**
Hereditary breast cancer **Hall A (Great Hall 1)**
- Chairperson:** **Nirmala Pathmanathan, Sydney, Australia**
- 12:30-13:20** Management of common genetic predisposition syndromes
Milita Zaheed, Sydney, Australia
- 13:20-14:00** The “extended panel” of genetic testing; implications and management
Helen Mar Fan, Brisbane, Australia
- 14:00-14:20* *Coffee break*
- 14:20-14:55** Molecular mechanisms, diagnostic and therapeutic implications of hereditary breast cancer syndromes
Sunil Lakhani, Brisbane, Australia
- 14:55-13:20** Psychological impact and management of patients with hereditary breast cancer
Jemma Gilchrist, Sydney, Australia
- 12:30-15:30** **Pre-Congress Workshop 5:**
Radiation oncology: Clinical updates and clinical challenges **Hall C (Room M1)**
- Chairperson:** **Marcus Dreosti, Adelaide, Australia**
- Speakers:**
Frank A. Vicini, Royal Oak, MI, USA
Boon Chua, Sydney, Australia
- 12:30-15:30** **Pre-Congress Workshop 6:**
Challenging communication **Hall D (Room M2)**
- Chairperson:** **Jenny Gilchrist, Sydney, Australia**
- 12:30-14:00** Cases and discussion
Jane Turner, Brisbane, Australia
- 14:00-14:20* *Coffee break*
- 14:20-15:30** Cases and discussion contd.

16:00-16:15 Congress Opening

Hall A (Great Hall 1)

Chairperson: **Bruce Mann**, *Melbourne, Australia*

Welcome to Country

Welcome from Congress chairpersons

16:15-17:45 **Plenary Session 1:**
Neoadjuvant therapy

Hall A (Great Hall 1)

Chairpersons: **Elisabeth Elder**, *Sydney, Australia*
Richard de Boer, *Melbourne, Australia*

16:15-16:45 **DEBATE:** That cT1cN0 HER2+ve and TNBC should have NAST

16:15 **Yes:** **Alistair Ring**, *London, UK*

16:25 **No:** **Nicholas Wilcken**, *Sydney, Australia*

16:35 Discussion

16:45-17:15 **Lessons Learnt:** The UK experience of Neo Adjuvant Endocrine Therapy (NAET) during the COVID pandemic

Stephen Johnston, *London, UK*

17:15-17:45 **DEBATE:** That LN positive patients achieving pCR with NAST should still receive regional nodal radiotherapy

17:15 **Yes:** **Frank A. Vicini**, *Royal Oak, MI, USA*

17:25 **No:** **Steven David**, *Melbourne, Australia*

17:35 Discussion

17:45 **Networking Reception**

Friday, October 14, 2022

07:30-08:30 **Morning Industry Symposium:**
The role of Enhertu (trastuzumab-deruxtecan) in changing the treatment paradigm for HER2-positive Metastatic Breast Cancer
Supported by AstraZeneca **Hall A (Great Hall 1)**

Breakfast will be served prior to the session

For full details, please refer to end of program

07:30-08:30 **Morning Industry Symposium:**
Supported by Genesis Care/PreludeDX **Hall B (Great Hall 2)**

Breakfast will be served prior to the session

For full details, please refer to end of program

07:30-08:30 **Morning Industry Symposium:**
Supported by Hologic **Hall C (Room M1)**

Breakfast will be served prior to the session

For full details, please refer to end of program

08:30-09:30 **Parallel Session 2:**
Screening **Hall A (Great Hall 1)**

Chairpersons: **Allison Rose, Melbourne, Australia**
Owen Ung, Brisbane, Australia

08:30-08:45 Tailored screening: The Netherlands experience
Ritse Mann, Nijmegen, The Netherlands

08:45-09:15	DEBATE: That women at low risk for breast cancer should only be screened every 5 years
08:45	Yes: Christobel Saunders, Melbourne, Australia
08:55	No: Jane Fox, Melbourne, Australia
09:05	Discussion

09:15-09:30 Risk adjusted screening: Considerations and lessons from COVID 19
Carolyn Nickson, Melbourne, Australia

08:30-09:30 **Parallel Session 3:**
Fear of cancer recurrence **Hall B (Great Hall 2)**

Chairpersons: **Kerry Shanahan, Melbourne, Australia**
Belinda Yeo, Melbourne, Australia

08:30-08:50 Fear of cancer recurrence: What is it, and how common is it?
Jane Turner, Brisbane, Australia

08:50-09:10 Is it possible to conquer fear of recurrence?
Charlotte Tottman, Adelaide, Australia

09:10-09:30 Discussion

08:30-09:30 **Morning Industry Symposium:**
Evolution of treatment sequencing in patients with mTNBC
Supported by Gilead **Hall C (Room M1)**

For full details, please refer to end of program

09:30-11:00 **Plenary Session 4:**
Genetics **Hall A (Great Hall 1)**

Chairpersons: **Nicole McCarthy, Brisbane, Australia**
Jane Fox, Melbourne, Australia

09:30-10:10	DEBATE: That ~all patients with breast cancer should be panel tested for germline mutations
09:30	Yes: Yoland Antill, Melbourne, Australia
09:45	No: Helen Mar Fan, Brisbane, Australia
10:00	Discussion

10:10-10:35 The 'new genes': What do they mean for patients and families?
Paul James, Melbourne, Australia

10:35-11:00 Tailored treatments for BRCA+ early breast cancer: The time is now!
Mark Robson, New York, NY, USA

11:00-11:30 *Coffee break and poster viewing*

11:30-12:30 **Parallel session 5:**
Lymphoedema **Hall A (Great Hall 1)**

Chairpersons: **Kerry Patford, Benalla, Australia**
Rajiv Dave, Manchester, UK

11:30-11:50 What is the evidence behind advice regarding lymphoedema prevention?
Louise Koelmeyer, Sydney, Australia

11:50-12:10 Evidence based treatment modalities for established lymphoedema: What works? What doesn't?
Robyn Box, Brisbane, Australia

12:10-12:30 Discussion

11:30-12:30 **Industry Symposium:**
Improving outcomes in high-risk HER2-positive patients post-KATHERINE
Supported by an educational/research sponsorship by Roche **Hall B (Great Hall 2)**

For full details, please refer to end of program

11:30-12:30 **Industry Symposium:**
Touch and go: Removing the guesswork in detecting residual cancer
Supported by OncoRes **Hall C (Room M1)**

For full details, please refer to end of program

12:30-13:30 *Lunch break and poster viewing*

13:30-14:30 **Parallel Session 6:**
DCIS

Hall A (Great Hall 1)

Chairpersons: **Steven David, Melbourne, Australia**
Caroline Baker, Melbourne, Australia

13:30-14:00	DEBATE: That most patients with DCIS should have radiotherapy after Breast Conserving Surgery
13:30	Yes: Boon H. Chua, Sydney, Australia
13:40	No: Alastair Thompson, Houston, TX, USA
13:50	Discussion

14:00-14:30	DEBATE: That active surveillance for low risk DCIS is a reasonable option
14:00	Yes: Jocelyn Lippey, Melbourne, Australia
14:10	No: Heidi Peverill, Brisbane, Australia
14:20	Discussion

13:30-14:30 **Parallel Session 7:**
Triple negative breast cancer

Hall B (Great Hall 2)

Chairpersons: **Nicholas Wilcken, Sydney, Australia**
Catherine Shannon, Brisbane, Australia

13:30-14:10	DEBATE: Immunotherapy should be part of standard of care in neoadjuvant treatment for TN ESBC
13:30	Yes: Rebecca Dent, Singapore, Singapore
13:45	No: Alistair Ring, London, UK
14:00	Discussion

14:10-14:30 TNBC subtypes and their clinical significance
Nirmala Pathmanathan, Sydney, Australia

13:30-14:30 **Parallel Session 8:**
Free Papers: Supportive Care

Hall C (Room M1)

Chairpersons: **Yoland Antill, Melbourne, Australia**

14:30-15:50 **Parallel Session 9:**
Adjuvant endocrine therapy

Hall A (Great Hall 1)

Chairpersons: **Prudence Francis, Melbourne, Australia**
 Richard de Boer, Melbourne, Australia

14:30-15:05	DEBATE: That CDK4/6i's should be part of adjuvant treatment of high-risk ER+HER2- early breast cancer
14:30	Yes: Shaheenah Dawood, Dubai, United Arab Emirates
14:40	No: Nick Zdenkowski, Newcastle, Australia
14:50	Discussion

15:05-15:15 Real world evidence and its value in breast cancer management?
Sheau Wen Lok, Melbourne, Australia

15:15-15:50	DEBATE: That all pre-menopausal women with LN+ve ER+HER2- EBC should have adjuvant chemotherapy
15:15	Yes: Nicole McCarthy, Brisbane, Australia
15:25	No: Belinda Yeo, Melbourne, Australia
15:35	Discussion

14:30-15:50 **Parallel Session 10:**
Free Papers: Locoregional therapy

Hall C (Room M1)

Chairpersons: **Michael Alvarado, San Francisco, CA, USA**
 Jill Dietz, Pittsburgh, PA, USA

15:50-16:10 *Coffee break and poster viewing*

16:10-17:30 **Parallel Session 11:**
Imaging

Hall A (Great Hall 1)

Chairpersons: **Jane Fox, Melbourne, Australia**
 Alastair Thompson, Houston, TX, USA

16:10-16:30 How can imaging assist management of patients receiving neoadjuvant therapy?
Julia Camps Herrero, Valencia, Spain

16:30-16:50 The PROSPECT of selective omission of RT based on MRI findings
Bruce Mann, Melbourne, Australia

16:50-17:10 That Contrast Enhanced Mammography (CEM) is ready for prime time
Allison Rose, Melbourne, Australia

17:10-17:30 Discussion

16:10-17:30 **Parallel Session 12:**
Metastatic breast cancer

Hall B (Great Hall 2)

Chairpersons: **Nick Zdenkowski, Newcastle, Australia**
Javier Cortes, Madrid, Spain

16:10-16:45	DEBATE: That molecular testing of tumours should be routine for patients with metastatic breast cancer
16:10	Yes: Elgene Lim, Sydney, Australia
16:20	No: TBA
16:30	Discussion

16:45-17:00 What's the optimal timing for Bone Targeted Agents in MBC?
Belinda Yeo, Melbourne, Australia

17:00-17:30	DEBATE: Routine imaging vs clinical follow-up for high risk EBC: Time to change the paradigm?
17:00	Yes: Sally Baron-Hay, Sydney, Australia
17:10	No: Catherine Shannon, Brisbane, Australia
17:20	Discussion

Saturday, October 15, 2022

07:30-08:30 **Morning Industry Symposium:**
Future-proofing breast surgical guidance with Sentimag®
A total magnetic conversion
Supported by Endomag/GRC Surgical

Hall A (Great Hall 1)

Breakfast will be served prior to the session

For full details, please refer to the end of the program

07:30-08:30 **Morning Industry Symposium:**
Supported by Lilly

Hall B (Great Hall 2)

Breakfast will be served prior to the session

For full details, please refer to the end of the program

08:30-10:00 **Parallel Session 13:
Controversies in reconstruction**

Hall A (Great Hall 1)

Chairpersons: **Kirsten Pilatti, Melbourne, Australia**
 Sanjay Warriar, Sydney, Australia

08:30-09:10	DEBATE: That immediate breast reconstruction prior to post-mastectomy radiotherapy should be avoided
08:30	Yes: Caroline Baker, Melbourne, Australia
08:40	No: Dean Trotter, Melbourne, Australia
08:50	Discussion

09:10-09:30 Patient-reported outcomes to guide decisions regarding breast reconstruction
Douglas MacMillan, Nottingham, UK

09:30-09:50 Consumer voice informing the future of breast reconstruction Australia
Sam Mills, Melbourne, Australia
Jodi Steel, Sydney, Australia

09:50-10:00 Discussion

08:30-10:00 **Parallel Session 14:
Survivorship**

Hall B (Great Hall 2)

Chairpersons: **Jenny Gilchrist, Sydney, Australia**
 Jocelyn Lippey, Melbourne, Australia

08:30-08:35 Introduction
Jenny Gilchrist, Sydney, Australia

08:35-08:45 What matters most to consumers?
Andrea Smith, Sydney, Australia

08:45-08:55 GP perspective
Elysia Thornton-Benko, Sydney, Australia

08:55-09:05 Survivorship MoC based around nurse led clinics
Kerry Shanahan, Melbourne, Australia

09:05-09:15 McGrath model of survivorship care
Kerry Patford, Benalla, Australia

09:15-09:25 #JustTextMe: Empowering women's health during survivorship
Anna Singleton, Sydney, Australia

09:25-09:35 IBIS
Raymond Chan, Adelaide, Australia

09:35-10:00 Discussion

08:30-10:00 **Parallel Session 15:**
Free Papers: Medical oncology **Hall C (Room M1)**

10:00-11:00 **Parallel Session 16:**
Locoregional therapy **Hall A (Great Hall 1)**

Chairpersons: **Heidi Peverill**, *Brisbane, Australia*
Caroline Baker, *Melbourne, Australia*

10:00-10:30	DEBATE: That patients with heavy axillary nodal disease pre-NACT should have axillary dissection irrespective of response to NACT
10:00	Yes: Alastair Thompson , <i>Houston, TX, USA</i>
10:10	No: Ben Green , <i>Brisbane, Australia</i>
10:20	Discussion

10:30-11:00	DEBATE: That omission of SNB should be considered for all women >70 with clinically negative axillae
10:30	Yes: Melanie Walker , <i>Melbourne, Australia</i>
10:40	No: Sanjay Warriar , <i>Sydney, Australia</i>
10:50	Discussion

10:00-11:00 **Industry Symposium:**
Supported by Novartis **Hall B (Great Hall 2)**

For full details, please refer to end of program

11:00-11:30 Coffee break and poster viewing

11:30-13:00 **Parallel Session 17:**
Local therapy **Hall A (Great Hall 1)**

Chairpersons: **Christobel Saunders**, *Melbourne, Australia*
Melanie Walker, *Melbourne, Australia*

11:30-12:30 **Time to cut the wire?**

11:30 That hook needles are perfectly satisfactory for lesion localisation
Owen Ung, *Brisbane, Australia*

11:40 The case for SCOUT
Cindy Mak, *Sydney, Australia*

11:50 The case for Magseed
Michael Alvarado, *San Francisco, CA, USA*

12:00 The case for ROLLIS
Rhea Liang, *Gold Coast, Australia*

12:10 Discussion

12:30-13:00	DEBATE: That five-fraction radiotherapy should be standard of care for most patients
12:30	Yes: Alice Ho , <i>Boston, MA, USA</i>
12:40	No: Frank A. Vicini , <i>Royal Oak, MI, USA</i>
12:50	Discussion

11:30-13:00 **Parallel Session 18:**
HER2 positive disease

Hall B (Great Hall 2)

Chairpersons: **Nicole McCarthy**, *Brisbane, Australia*
Elgene Lim, *Sydney, Australia*

11:30-12:15	DEBATE: Do anthracyclines still have a place in the treatment of early stage HER2+ve BC?
11:30	Yes: Nick Murray , <i>Adelaide, Australia</i>
11:45	No: Fran Boyle , <i>Sydney, Australia</i>
12:00	Discussion

12:15-12:35 HER2 heterogeneity: Interpretation of low HER2 amplification and HER+ve hotspots
Cameron Snell, *Melbourne, Australia*

12:35-13:00 Management of brain mets in those with HER2+ve disease
Rebecca Dent, *Singapore, Singapore*

13:00-14:00 *Lunch break and poster viewing*

13:10-13:55 **Industry Lunch Symposium:**
Supported by 3M

Hall B (Great Hall 2)

For full details, please refer to end of program

14:00-15:00 **Plenary Session 19:**
Palliative care

Hall A (Great Hall 1)

Chairpersons: **Fran Boyle, Sydney, Australia**
 Nick Murray, Adelaide, Australia

14:00-14:30	DEBATE: That palliative care should ditch the word 'palliative'
14:00	Yes: Brian Le, Melbourne, Australia
14:10	No: Andrew Broadbent, Gold Coast, Australia
14:20	Discussion

14:30-15:00 Medicinal cannabis in advanced cancer: Pot or panacea?
Phillip Good, Brisbane, Australia

15:00-16:15 **Plenary Session 20:**
Breast cancer 2030

Hall A (Great Hall 1)

Chairpersons: **Bruce Mann, Melbourne, Australia**
 Richard de Boer, Melbourne, Australia

15:00-15:15 Early detection in 2030
Ritse Mann, Nijmegen, The Netherlands

15:15-15:30 A pathologist's view of breast cancer in 2030
Sunil R. Lakhani, Brisbane, Australia

15:30-15:45 Systemic therapy in 2030
Prudence Francis, Melbourne, Australia

15:45-16:00 Locoregional therapy in 2030
Douglas MacMillan, Nottingham, UK

16:00-16:15 A consumer's perspective of breast cancer in 2030
Kirsten Pilatti, Melbourne, Australia

16:15-16:30 **Congress closing and Award presentation**

Hall A (Great Hall 1)

Chairpersons: **Bruce Mann, Melbourne, Australia**
 Melanie Walker, Melbourne, Australia
 Elisabeth Elder, Sydney, Australia

Industry Symposia

Friday, October 14, 2022

07:30-08:30 **Morning Industry Symposium:**
The role of Enhertu (trastuzumab-deruxtecan) in changing the treatment paradigm for HER2-positive Metastatic Breast Cancer
Supported by AstraZeneca **Hall A (Great Hall 1)**

Breakfast will be served prior to the session

07:30-08:30 **Morning Industry Symposium:**
DCISionRT: Personalising treatment for women with DCIS
Supported by Genesis Care/PreludeDX **Hall B (Great Hall 2)**

Breakfast will be served prior to the session

Delivering precision medicine to women with DCIS in Australia: Clinical application and how it has changed the management of women with DCIS

Bruce Mann, Melbourne, Australia

Science and clinical evidence: Consistent predictor of radiation therapy benefit

Troy Bremer, Laguna Hills, CA, USA

Future advances in DCISionRT testing

Frank A. Vicini, Royal Oak, MI, USA

Interim analysis of the PREDICT Registry Australia: Impact on treatment recommendations

Yvonne Zissiadis, Perth, Australia

07:30-08:30 **Morning Industry Symposium:**
Supported by Hologic **Hall C (Room M1)**

Breakfast will be served prior to the session

Speaker: Allison Rose, Melbourne, Australia

08:30-09:30 **Morning Industry Symposium:**
Evolution of treatment sequencing in patients with mTNBC
Supported by Gilead **Hall C (Room M1)**

Chairperson: Richard de Boer, Melbourne, Australia

Panel: Australian patient cases for discussion

11:30-12:30 **Industry Symposium:**
Improving outcomes in high-risk HER2-positive patients post-KATHERINE
Supported by an educational/research sponsorship by Roche **Hall B (Great Hall 2)**

Chairperson: **Richard de Boer, Melbourne, Australia**

Speaker: **Javier Cortes, Madrid, Spain**

Panelists: **Elgene Lim, Sydney, Australia**
Nicole McCarthy, Brisbane, Australia

11:30-12:30 **Industry Symposium:**
Touch and go: Removing the guesswork in detecting residual cancer
Supported by OncoRes **Hall C (Room M1)**

Chairperson: **Christobel Saunders, Melbourne, Australia**

Speakers: **Christobel Saunders, Melbourne, Australia**
Helen Ballal, Perth, Australia

OncoRes Medical is developing an intraoperative imaging technology to provide surgeons with real-time assessment of tissue microstructure in the surgical cavity. Hosted by Professor Christobel Saunders AO, Dr Helen Ballal, and OncoRes Medical, this symposium presents the latest developments and an interactive demonstration of the technology.

Saturday, October 15, 2022

07:30-08:30 **Morning Industry Symposium:**
Future-proofing breast surgical guidance with Sentimag®
A total magnetic conversion
Supported by Endomag/GRC Surgical **Hall A (Great Hall 1)**

Breakfast will be served prior to the session

Chairpersons: **Bruce Mann, Melbourne, Australia**
Emilia Dauway, Urraween, QLD, Australia

07:30-07:40 1,000 Magseed® vs 1,000 Wires: Findings from iBRA-NET, the world's largest non-radioactive localization seed comparative study
Rajiv Dave, Manchester, UK

07:40-07:50 The SLNB evolution: advantages of switching to a non-radioactive approach with Magtrace®
Jill Dietz, Pittsburgh, PA, USA

07:50-08:00 Sentimag®: A complete magnetic approach for Targeted Axillary Dissection (TAD) and other advanced techniques
Michael Alvarado, San Francisco, CA, USA

08:00-08:05 A sneak preview of the new Sentimag® platform

08:05-08:30 Discussion

07:30-08:30 **Morning Industry Symposium:**
Time to start CDK4&6 inhibition in EBC. Verzenio in node positive, early breast cancer at high risk of recurrence
Supported by Lilly **Hall B (Great Hall 2)**

Breakfast will be served prior to the session

10:00-11:00 **Industry Symposium:**
A CDK4/6i is a ‘once in a lifetime treatment’ for patients with HR +ve HER2 -ve breast cancer
Supported by Novartis **Hall B (Great Hall 2)**

Chairperson: **Nicholas Wilcken, Sydney, Australia**

Debate:

A CDK4/6i is a ‘once in a lifetime treatment’ for patients with HR +ve HER2 -ve breast cancer

13:10-13:55 **Industry Lunch Symposium:**
Innovative approaches to help improve patient outcomes:
Case-based discussion
Supported by 3M **Hall B (Great Hall 2)**

Chairperson: **Elisabeth Elder, Sydney, Australia**

Speakers:

Matthew M. Cooper, St. Paul, Minnesota, USA

Tripp Holton, Annapolis, MD, USA